He upped the ante in his ongoing dispute with Herbalife, saying Wednesday that the company already has been shut down but hasn't acknowledged it. » Read More
Investors are fleeing from Bill Ackman's hedge fund, withdrawing $600 million during the first six months of the year according to Fortune.
Herbalife Ltd., up $5.90 to $65.26. Wells Fargo& Co., down $1.23 to $47.71. Infosys Ltd., down $1.63 to $16.81.
Herb Greenberg, Pacific Crest Research, reacts to FTC Chairwoman Edith Ramirez's announcement.
CNBC's Kate Kelly reports on the settlement between the FTC and Herbalife, and just how much Pershing Square's Bill Ackman is losing.
Friday's ruling that Herbalife isn't a Ponzi scheme adds another layer to an already brutal year for hedge fund titan Bill Ackman.
The "FMHR" traders and John Spallanzani, GFI Group Chief Macro Strategist, discuss Ackman's response to the FTC Herbalife settlement.
Robert Chapman, Chapman Capital, comments on Herbalife's $200M agreement with FTC, as well as his views on the future of its stock.
Tim Ramey, Pivotal Research Analyst, comments on the $200M Herbalife settlement with FTC.
Shares in the nutritional supplement marketer jumped 10 percent in premarket trading on the news.
FTC Chairwoman Edith Ramirez announces the settlement with Herbalife. CNBC's David Faber provides perspective.
These are the stocks posting the largest moves early Friday.
Carl Icahn, Herbalife's largest shareholder releases a statement after the FTC announces it reached a $200 million settlement with Herbalife.
NEW YORK— Federal regulators closed an investigation of the multinational, nutritional supplements company Herbalife, which has for years been dogged by accusations that it was run as an elaborate pyramid scheme. Though Herbalife was ordered to restructure its U.S. operations and pay a $200 million settlement Friday, it avoided being classified by the U.S. as...
The FTC and Herbalife have reached an agreement, reports CNBC's Scott Wapner.
Shares of Herbalife are up in the pre-market on word the FTC is expected to announce a settlement today with Herbalife.
Bill Ackman discussed his latest views on Herbalife, Valeant Pharmaceuticals and Mondelez in an extensive interview with CNBC's Scott Wapner on Thursday.
Herb Greenberg, Pacific Square Research Partner, and CNBC's Scott Wapner, discuss Bill Ackman's attack on Herbalife's business model.
He said that while it's likely there will come a day where Valeant sells off its non-core assets, Bausch & Lomb will not be one.
Bill Ackman, Pershing Square CEO, responds to Herbalife's statement on Ackman's short.
Bill Ackman, Pershing Square CEO, discusses his firm escalating the attack on Herbalife with a new video series.